Keep up to date
Press release | 03.10.2019
Univercells boosted by EUR 20M European financing to accelerate the delivery of its vaccine portfolio
Financing to support Univercells’ R&D investments to develop four essential and undersupplied global health vaccines to be produced at affordable ...
Univercells news | 10.07.2019
Univercells expands its development capacity with modular laboratories
400 m² extension will enable the company to pursue the development of its viral vaccines' portfolio addressing global health challenges
Press release | 13.06.2019
Univercells granted $14.3M to deliver affordable measles & rubella vaccines
Univercells announces today second grant from the Bill & Melinda Gates Foundation to develop a cost-effective manufacturing process and proceed ...
Univercells news | 17.04.2019
Introducing the scale-X™ carbo bioreactor system
The scale-X™ carbo is a bench-scale automated cell culture system for expression and concentration of viral drug substance, suited for ...
In the press | 01.04.2019
Reinventing the Biomanufacturing Wheel
Our Product Manager Tania explains the challenges in biologic manufacturing and Univercells' solutions in BioParhm International article
Univercells news | 27.03.2019
Univercells joins the Belgian State Visit to South Korea
Belgian State Visit to Korea - Hugues Bultot, CEO of Univercells, joins the Belgian business delegation to strengthen and further ...
Univercells news | 21.02.2019
Univercells presents NevoLine™ biomanufacturing system
Based on a novel process architecture, Univercells designed the automated NevoLine bioproduction system that facilitates safer, faster and closed bioprocessing ...
In the press | 14.02.2019
A Brief History of Adherent Cell Culture
Our Product Manager Alex Chatel explains the evolution of cell culture from the materials used - suspension cells to adherent cells ...